Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 9/20 | 0.56 |
| ▸ | CDK9 | P50750 | 9/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390402 | 0.88 | CCNT1 (0.46) | CCNT1CDK9HDAC1NPY5R | |
| SCHEMBL5301923 | 0.83 | POLB (0.45) | CCNT1CDK9HDAC1NPY5R | |
| SCHEMBL1831290 | 0.81 | IDO1 (0.44) | CCNT1CDK9HDAC1 | |
| SCHEMBL29427115 | 0.81 | IDO1 (0.44) | CCNT1CDK9HDAC1 | |
| SCHEMBL9445966 | 0.81 | TAAR1 (0.46) | CCNT1CDK9HDAC1 | |
| SCHEMBL1759923 | 0.80 | IDO1 (0.43) | CCNT1CDK9HDAC1NPY5R | |
| SCHEMBL9502876 | 0.80 | CCNT1 (0.42) | CCNT1CDK9HDAC1NPY5R | |
| SCHEMBL1307260 | 0.80 | IDO1 (0.43) | CCNT1CDK9HDAC1MAOB | |
| SCHEMBL1305912 | 0.80 | CYP3A4 (0.43) | CCNT1CDK9HDAC1TP53CYP3A4 | |
| SCHEMBL29938481 | 0.80 | IDO1 (0.43) | CCNT1CDK9HDAC1MAOBNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954258-B2 | STAT3 dimerization inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954258-B2 | STAT3 dimerization inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200199160-A1 | STAT3 DIMERIZATION INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200199160-A1 | STAT3 DIMERIZATION INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20180179235-A1 | STAT3 DIMERIZATION INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179235-A1 | STAT3 DIMERIZATION INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179235-A1 | STAT3 DIMERIZATION INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-28 | — | — | US | disclosed |
| US-9822135-B2 | STAT3 dimerization inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822135-B2 | STAT3 dimerization inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822135-B2 | STAT3 dimerization inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| CN-101074242-A | Cells accumulation for sphosphonate analogs of HIV protease inhibitor compound and the same compound | GILEAD SCIENCES INC (US) | 2007-11-21 | — | — | CN | disclosed |
| CN-1313472-C | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2007-05-02 | — | — | CN | disclosed |
| CN-1649885-A | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| EP-0769015-B1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-03-14 | — | — | EP | disclosed |
| US-5770615-A | Catecholamine surrogates useful as β3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-23 | — | — | US | disclosed |
| US-5716944-A | USEFUL AS PROPHYLACTIC AND THERAPEUTIC AGENTS OF VARIOUS METABOLIC BONE DISEASES SUCH AS OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| WO-1997037646-A1 | CATECHOLAMINE SURROGATES USEFUL AS β3 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-10-16 | — | — | WO | disclosed |
| CN-1151744-A | Phosphonic acid compounds, their prodn. and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-06-11 | — | — | CN | disclosed |
| EP-0769015-A1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001267-A1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199160-A1 | STAT3 DIMERIZATION INHIBITORS | STAT3, JAK2, STAT1 | CCNT1 2398/4885CDK9 228/4885HDAC1 319/4885 |
| US-20180179235-A1 | STAT3 DIMERIZATION INHIBITORS | STAT3, JAK2, STAT1 | CCNT1 2398/4885CDK9 228/4885HDAC1 319/4885 |
| US-10954258-B2 | STAT3 dimerization inhibitors | STAT3, JAK2, STAT1 | CCNT1 2398/4885CDK9 228/4885HDAC1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.